Stocks · News reference
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.